GlassScriptPhysician profile
Ramesh H Rathod
NPI 1396732855
$5,716.12
in general payments reported to CMS, 2019-2025
25 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $149 · 2021: $293 · 2022: $1,172 · 2023: $809 · 2024: $1,082 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $768.15 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console, Diamondback Coronary |
| Pfizer INC. | $762.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $546.97 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.20 | 2019-2025 | Jardiance |
| Abiomed | $447.10 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $343.46 | 2019-2025 | Lifevest |
| Amgen INC. | $286.60 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $268.84 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $249.86 | 2019-2022 | |
| Atricure, INC. | $200.12 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $191.38 | 2022-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $188.87 | 2019-2023 | Watchman Access System |
| Medtronic Vascular, INC. | $156.07 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $141.92 | 2019 | |
| Medtronic, INC. | $139.41 | 2022-2024 | Linq II |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $123.05 | 2021-2024 | Verquvo |
| Shockwave Medical, INC | $119.44 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $108.33 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $45.50 | 2023-2024 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $43.62 | 2022-2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $35.18 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $33.20 | 2025 | Evkeeza |
| Scpharmaceuticals INC. | $25.54 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.86 | 2020 | |
| Chiesi USA, INC. | $15.88 | 2025 | Juxtapid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Rathod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.